Alternative Name: Miglustat; N-butyldeoxynojirimycin (NB-DNJ)

Description: Zavesca, a medication already approved for treating a rare genetic disorder, works as a male contraceptive for a particular strain of laboratory mouse. Exactly how Zavesca acts as a contraceptive for the mice is not known.

Product Details

User: Male

Hormonal: No

Delivery Method: Oral

Duration Type: Permanent

Active Pharmaceutical Ingredient (API):
  • Miglustat

Multipurpose Preventive Technology (MPT): No

Status Details

Developer: University of Washington, Oxford GlycoSciences

Project Phase: Discovery and Early Development

Development Stage: Lead Optimization

Active Development: No

Status Details:
  • Research on Zavesca as a male contraceptive has stopped as it was shown to not be effective in humans.

Additional Information


Vertical Tabs